Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: Ipsen sa | History Defined

3 Specialty Pharma Stocks Addressing Unmet Medical Needs

The specialty pharma sector is leading the charge in developing life-changing solutions for rare and chronic conditions. Amid this backdrop, investors might consider adding three fundamentally solid specialty pharma stocks, namely, Ipsen S.A. (IPSEY), ACADIA Pharmaceuticals (ACAD), and Neurocrine Biosciences (NBIX) in their portfolios. Read on….

StockNews.com

3 Mid-Cap Stocks With Big Cap Potential

With the steady growth in the global economy and other supportive aspects like easing inflation and the possibility of interest rate cuts, mid-cap stocks present great opportunities. Thus, fundamentally sound mid-cap stocks Pilgrim’s Pride (PPC), Ipsen (IPSEY), and Isuzu Motors (ISUZY) could be ideal buys. Keep reading.

StockNews.com

3 A-Rated Pharma Stocks to Boost Your Bottom Line

The pharmaceutical industry is experiencing rapid growth thanks to healthcare demand, regulatory initiatives, and technological adoption in drug discovery and development. Hence, it could be wise to invest in pharma stocks Ipsen (IPSEY), Bristol-Myers (BMY), and Taro Pharmaceutical (TARO) to drive your bottom line. These stocks are rated A (Strong…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Pharma Stocks With Prescription for Stability and Value in March

Amid rising healthcare demand globally, advancements in precision medicine, and the booming e-pharmacy market, the pharmaceutical industry is expected to witness significant long-term growth. Hence, fundamentally sound pharma stocks Dr. Reddy’s Laboratories (RDY), Ipsen (IPSEY), and Johnson & Johnson (JNJ), which boast low beta values and attractive valuation metrics, might…

StockNews.com

5 Pharma Stocks to Watch With Bullish Momentum

The pharma industry is poised for robust expansion this year with rising demand and technological advancement in the sector. Hence, investors might watch fundamentally solid pharma stocks Procaps Group (PROC), Sanofi (SNY), Viatris (VTRS), Ipsen (IPSEY), and Teva Pharmaceutical Industries (TEVA) for solid gains. Read on.

StockNews.com

Top 4 Pharma Stocks on the Rise for Potential Gains

Growing medical needs, surging demand for precision medicine, favorable regulatory climate, and rapid digital transformation would create promising growth opportunities for pharma companies. Hence, it could be wise to invest in top pharma stocks Johnson & Johnson (JNJ), Spero Therapeutics (SPRO), Ipsen (IPSEY), and Procaps Group (PROC) for solid gains.…

StockNews.com

3 Pharma Stocks Providing Consistent Gains for Investors

The pharmaceutical industry is anticipated to be bolstered due to the increasing demand for chronic disease management and the rising requirements of an aging demographic. Given the industry’s solid prospects, investors could buy quality pharma stocks Eton Pharmaceuticals (ETON), Ipsen S.A. (IPSEY), and Merck & Co. (MRK) for consistent gains.…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Undervalued Pharma Stocks Worth Buying

With the growing prevalence of chronic diseases, the adoption of advanced digital technologies, and new drug discoveries, the pharmaceutical industry is set to witness significant growth this year and beyond. Thus, it could be wise to invest in quality pharma stocks Ipsen (IPSEY), Supernus (SUPN), and Kamada (KMDA), which are…

StockNews.com

Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer

The European Commission (EC) has approved Ipsen SA's (OTC:IPSEY) Cabometyx (cabozantinib) as monotherapy in differentiated thyroid carcinoma (DTC) setting. The approval covers adult patients with locally advanced or metastatic DTC, refractory or not eligible for radioactive iodine, who have progressed during or after systemic therapy. This EC approval follows the FDA approval announced…

Benzinga

People

Kritika SarmahHer

727 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.